Latest Content

Teclistamab shows promising real-world effectiveness and safety in older adults with relapsed/refractory multiple myeloma (R/R MM), matching clinical trial outcomes.

Medicare beneficiaries with near low income experience more affordability issues than beneficiaries with low income due to Medicare savings programs eligibility.

New research reveals that changes in normal-appearing white and gray matter significantly impact MS progression, challenging traditional lesion-focused views.

Oral nicotinamide reduced the risk of new skin cancers—especially squamous cell carcinoma—by up to 54% when started after a first diagnosis.

These patients had a higher spleen-to-liver stiffness ratio than those with alcohol-related liver disease, warranting a closer look at testing.

Funding cuts to childhood cancer research have put the subspecialty in a precarious position during Childhood Cancer Awareness Month.

The ease of acquiring prior authorizations for a new formulary drug plays a part in evaluating oncology drugs that are new to the market.

The Trump administration highlighted a potential autism risk from prenatal acetaminophen use, but studies demonstrate conflicting evidence.

Only a fraction of countries in the world have designated chronic kidney disease as a health priority.